A-FIB
MCID: ATR011
MIFTS: 66

Atrial Fibrillation (A-FIB) malady

Categories: Cardiovascular diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Atrial Fibrillation

Aliases & Descriptions for Atrial Fibrillation:

Name: Atrial Fibrillation 12 29 52 41 3 42 14 69
a-Fib 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060224
ICD10 33 I48
ICD9CM 35 427.31
MeSH 42 D001281
NCIt 47 C50466
UMLS 69 C0004238

Summaries for Atrial Fibrillation

MedlinePlus : 41 an arrhythmia is a problem with the speed or rhythm of the heartbeat. atrial fibrillation (af) is the most common type of arrhythmia. the cause is a disorder in the heart's electrical system. often, people who have af may not even feel symptoms. but you may feel palpitations -- an abnormal rapid heartbeat shortness of breath weakness or difficulty exercising chest pain dizziness or fainting fatigue confusion af can lead to an increased risk of stroke. in many patients, it can also cause chest pain, heart attack, or heart failure. doctors diagnose af using family and medical history, a physical exam, and a test called an electrocardiogram (ekg), which looks at the electrical waves your heart makes. treatments include medicines and procedures to restore normal rhythm. nih: national heart, lung, and blood institute

MalaCards based summary : Atrial Fibrillation, also known as a-fib, is related to atrial fibrillation, familial, 3 and atrial fibrillation, familial, 10, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Atrial Fibrillation is GJA5 (Gap Junction Protein Alpha 5), and among its related pathways/superpathways are Vascular smooth muscle contraction and G-Beta Gamma Signaling. The drugs Amiodarone and Propafenone have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and lung, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A heart conduction disease that is characterized by uncoordinated electrical activity in the heart's upper chambers (the atria), which causes the heartbeat to become fast and irregular and has symptoms palpitations, weakness, fatigue, lightheadedness, dizziness, confusion, shortness of breath and chest pain.

CDC : 3 Electrical activity of a normal heart (left) and a heart with atrial fibrillation (right).

Wikipedia : 71 Atrial fibrillation (AF or A-fib) is an abnormal heart rhythm characterized by rapid and irregular... more...

Related Diseases for Atrial Fibrillation

Diseases in the Atrial Fibrillation family:

Atrial Fibrillation, Familial, 6 Atrial Fibrillation, Familial, 11
Atrial Fibrillation, Familial, 10 Atrial Fibrillation, Familial, 5
Atrial Fibrillation 15 Atrial Fibrillation, Familial, 2
Atrial Fibrillation, Familial, 1 Atrial Fibrillation, Familial, 3
Atrial Fibrillation, Familial, 14 Atrial Fibrillation, Familial, 7
Atrial Fibrillation, Familial, 12 Atrial Fibrillation, Familial, 8
Atrial Fibrillation, Familial, 9 Atrial Fibrillation, Familial, 13
Atrial Fibrillation, Familial, 4 Familial Atrial Fibrillation
Kcne5-Related Atrial Fibrillation Nppa-Related Familial Atrial Fibrillation 6
Scn2b-Related Familial Atrial Fibrillation Abcc9-Related Familial Atrial Fibrillation
Gja5-Related Familial Atrial Fibrillation Kcna5-Related Familial Atrial Fibrillation
Kcne2-Related Familial Atrial Fibrillation Kcnj2-Related Familial Atrial Fibrillation
Kcnq1-Related Familial Atrial Fibrillation Myl4-Related Familial Atrial Fibrillation
Scn1b-Related Familial Atrial Fibrillation Scn3b-Related Familial Atrial Fibrillation
Scn5a-Related Familial Atrial Fibrillation

Diseases related to Atrial Fibrillation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 291)
id Related Disease Score Top Affiliating Genes
1 atrial fibrillation, familial, 3 33.3 KCNA5 KCNE1 KCNE2 KCNJ2 KCNQ1 SCN3B
2 atrial fibrillation, familial, 10 33.3 KCNE1 KCNE2 KCNQ1 SCN1B SCN2B SCN3B
3 short qt syndrome 2 31.5 KCNE1 KCNE2 KCNQ1 SCN4B SCN5A
4 rheumatic heart disease 30.6 GJA5 HCN4 SCN5A
5 myocardial infarction 29.8 ACE ADRB1 AGT F2 NPPA NPPB
6 pyelonephritis 29.5 ACE F2 NPPA NPPB
7 third-degree atrioventricular block 29.3 HCN4 KCNE1 KCNE2 KCNQ1 NPPB SCN5A
8 familial atrial fibrillation 12.6
9 atrial fibrillation, familial, 12 12.3
10 atrial fibrillation, familial, 6 12.3
11 atrial fibrillation, familial, 11 12.3
12 atrial fibrillation, familial, 9 12.3
13 atrial fibrillation, familial, 4 12.3
14 atrial fibrillation, familial, 7 12.3
15 atrial fibrillation 15 12.3
16 atrial fibrillation, familial, 13 12.3
17 atrial fibrillation, familial, 14 12.3
18 myl4-related familial atrial fibrillation 12.3
19 atrial fibrillation, familial, 1 12.3
20 atrial fibrillation and stroke 12.3
21 atrial fibrillation, familial, 2 12.2
22 atrial fibrillation, familial, 8 12.2
23 nppa-related familial atrial fibrillation 6 12.0
24 abcc9-related familial atrial fibrillation 12.0
25 gja5-related familial atrial fibrillation 12.0
26 kcna5-related familial atrial fibrillation 12.0
27 kcnj2-related familial atrial fibrillation 12.0
28 scn1b-related familial atrial fibrillation 12.0
29 atrial fibrillation, familial, 5 11.9
30 scn2b-related familial atrial fibrillation 11.9
31 kcne2-related familial atrial fibrillation 11.9
32 kcnq1-related familial atrial fibrillation 11.9
33 scn3b-related familial atrial fibrillation 11.9
34 scn5a-related familial atrial fibrillation 11.9
35 kcne5-related atrial fibrillation 11.9
36 brugada syndrome 7 11.8
37 long qt syndrome-10 11.7
38 pulmonary vein stenosis 11.3
39 short qt syndrome 3 11.2
40 coumarin resistance 11.1
41 mcleod syndrome with or without chronic granulomatous disease 11.0
42 sick sinus syndrome 2 10.9
43 cardiac arrhythmia, ankyrin-b-related 10.9
44 congenital heart defects, nonsyndromic, 2 10.9
45 short qt syndrome 1 10.9
46 rheumatic fever 10.9
47 hereditary amyloidosis 10.8
48 mitral valve disease 10.6
49 wolff-parkinson-white syndrome 10.5
50 sick sinus syndrome 10.4

Graphical network of the top 20 diseases related to Atrial Fibrillation:



Diseases related to Atrial Fibrillation

Symptoms & Phenotypes for Atrial Fibrillation

UMLS symptoms related to Atrial Fibrillation:


angina pectoris, chest pain, edema

MGI Mouse Phenotypes related to Atrial Fibrillation:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 HCN4 KCNA5 KCNJ2 KCNQ1 NPPA NUP155
2 homeostasis/metabolism MP:0005376 9.93 ACE ADRB1 AGT F2 GJA5 KCNA5
3 muscle MP:0005369 9.61 ADRB1 AGT GJA5 HCN4 KCNA5 KCNJ2
4 normal MP:0002873 9.23 F2 GJA5 HCN4 KCNQ1 SCN1B SCN4B

Drugs & Therapeutics for Atrial Fibrillation

Drugs for Atrial Fibrillation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 489)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amiodarone Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 1951-25-3 2157
2
Propafenone Approved Phase 4,Phase 3,Phase 2,Phase 1 54063-53-5 4932
3
Sotalol Approved Phase 4,Phase 3,Phase 2,Phase 1 959-24-0, 3930-20-9 5253
4
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
5
Menthol Approved Phase 4,Phase 3,Phase 2 2216-51-5 16666
6
Diltiazem Approved Phase 4,Phase 3,Phase 1 42399-41-7 39186
7
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
8
Rivaroxaban Approved Phase 4,Phase 3,Phase 2,Phase 1 366789-02-8
9
Ticagrelor Approved Phase 4,Phase 3,Phase 1 274693-27-5 9871419
10
Warfarin Approved Phase 4,Phase 3,Phase 2,Phase 1 81-81-2 6691 54678486
11
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
12
Acenocoumarol Approved Phase 4,Phase 3,Phase 2 152-72-7 9052 54676537
13
Salicylic acid Approved, Vet_approved Phase 4,Phase 3 69-72-7 338
14
Ticlopidine Approved Phase 4,Phase 3 55142-85-3 5472
15
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
16
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
17
Enfuvirtide Approved, Investigational Phase 4 159519-65-0 16130199
18
Phenprocoumon Approved Phase 4,Phase 3 435-97-2 9908 54680692
19
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
20
Amlodipine Approved Phase 4 88150-42-9 2162
21
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
22
Simvastatin Approved Phase 4,Phase 2 79902-63-9 54454
23
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
24
Ranolazine Approved, Investigational Phase 4,Phase 2,Phase 3 142387-99-3, 95635-55-5 56959
25
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2 9005-49-6 772 46507594
26
Nicorandil Approved Phase 4 65141-46-0 47528
27
Ibutilide Approved Phase 4 122647-32-9, 122647-31-8 60753
28
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 37350-58-6, 51384-51-1 4171
29
Digoxin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-75-5 30322 2724385
30
Dalteparin Approved Phase 4,Phase 3,Phase 2 9041-08-1
31
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2 58-61-7 60961
32
Procainamide Approved Phase 4,Phase 3 51-06-9 4913
33
Candesartan Approved Phase 4,Phase 3 139481-59-7 2541
34
Sevoflurane Approved, Vet_approved Phase 4,Phase 1,Phase 2 28523-86-6 5206
35
Spironolactone Approved Phase 4,Phase 2,Phase 3 1952-01-7, 52-01-7 5833
36
Bisoprolol Approved Phase 4,Early Phase 1 66722-44-9 2405
37
Carvedilol Approved, Investigational Phase 4,Phase 3 72956-09-3 2585
38
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
39
Colchicine Approved Phase 4,Phase 3,Phase 2 64-86-8 6167 2833
40
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
41
Ephedrine Approved Phase 4 299-42-3 9294
42
Oxymetazoline Approved Phase 4,Phase 2 1491-59-4 4636
43
Phenylephrine Approved Phase 4,Phase 2 59-42-7 6041
44
Pseudoephedrine Approved Phase 4 90-82-4 7028
45
Iron Approved Phase 4,Phase 3 7439-89-6 23925
46
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 2078-54-8 4943
47
Losartan Approved Phase 4,Phase 3 114798-26-4 3961
48
Nifedipine Approved Phase 4 21829-25-4 4485
49
Dofetilide Approved Phase 4,Phase 3 115256-11-6 71329
50
Quinidine Approved Phase 4,Phase 3 56-54-2 441074

Interventional clinical trials:

(show top 50) (show all 1922)
id Name Status NCT ID Phase
1 Cardioversion vs. Catheter Ablation for Persistent Atrial Fibrillation Unknown status NCT00196209 Phase 4
2 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Unknown status NCT00724581 Phase 4
3 Line Versus Spot Ablation in Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
4 Atrial Fibrillation and the Risk for Neurological Complications Unknown status NCT00357227 Phase 4
5 Left Atrial Ablation of Paroxysmal Atrial Fibrillation With Implantable Loop Recorder Follow Up Study: The LAAPITUP 2 Study Unknown status NCT01504451 Phase 4
6 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4
7 Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study Unknown status NCT01850277 Phase 4
8 Vernakalant Versus Flecainide: Atrial Contractility Unknown status NCT01646281 Phase 4
9 Efficacy and Safety Study of Catheter Ablation for Atrial Fibrillation Unknown status NCT01113294 Phase 4
10 Catheter Ablation Versus Antiarrythmic Drugs for Atrial Fibrillation in China Unknown status NCT01341353 Phase 4
11 Dronedarone in Pacemakers Patients With Paroxysmal Atrial Fibrillation Unknown status NCT01070667 Phase 4
12 DAPPAR AF Dabigatran for Peri Procedural Anticoagulation During Radiofrequency Ablation of Atrial Fibrillation Unknown status NCT01468155 Phase 4
13 Pulmonary Vein (PV) -Isolation: Arrhythmogenic Vein(s) Versus All Veins Unknown status NCT00605748 Phase 4
14 Low Dose of Diltiazem for Rate Control of Atrial Fibrillation Unknown status NCT00834925 Phase 4
15 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4
16 The Contact PVI Study: Use of Tissue Contact Data to Guide Atrial Fibrillation Ablation Unknown status NCT01629056 Phase 4
17 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4
18 A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy Unknown status NCT00773539 Phase 4
19 EvaluAtion of Predictive Value of Multisite Intracardiac EchoCardiography During Imaging of Structure and funCTION of Left Atrial Appendage in Comparison to Transesophageal Echocardiography Unknown status NCT01371279 Phase 4
20 Irbesartan and Adhesion Molecules in AF Unknown status NCT00613496 Phase 4
21 Anticoagulation in Stent Intervention Unknown status NCT01141153 Phase 4
22 Mode Evaluation in Sick Sinus Syndrome Trial (MODEST) Unknown status NCT00161551 Phase 4
23 Corticosteroid Pulse After Ablation Unknown status NCT00807586 Phase 4
24 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
25 Ventricular Pacing Site Selection (V-PASS) Unknown status NCT00292383 Phase 4
26 Treatment of Subclinical Hyperthyroidism Unknown status NCT00213720 Phase 4
27 The Efficacy and Safety of CARTO 3D Mapping System Versus Conventional Method in AF and VT Unknown status NCT00959205 Phase 4
28 Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation Unknown status NCT00776633 Phase 4
29 Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4
30 The Study of Warfarin Maintenance Dose in Chinese Patients Unknown status NCT01855737 Phase 4
31 RAAS Inhibitor Drugs in Dialysis Patients Unknown status NCT01635387 Phase 4
32 Right Ventricular Septal Pacing for the Prevention of Left Ventricular Dysfunction in Patients With Atrio-Ventricular Block Unknown status NCT00709774 Phase 4
33 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
34 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
35 Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients Unknown status NCT01394770 Phase 4
36 Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients Unknown status NCT01011660 Phase 4
37 Safety of Amiodarone and Ranolazine Together in Patients With Angina Unknown status NCT01558830 Phase 4
38 Evaluation of the Efficacy and Safety of Levothyroxine in Brain Death Organ Donors: a Randomized Controled Trial Unknown status NCT02211053 Phase 4
39 Steroids In caRdiac Surgery Trial (SIRS Trial) Unknown status NCT00427388 Phase 4
40 Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4
41 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit Completed NCT01461733 Phase 4
42 Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation Completed NCT00863213 Phase 4
43 Nifedipine vs Telmisartan on Prevention of Atrial Fibrillation (AF) Recurrence in Hypertensive Patients With AF Completed NCT01435161 Phase 4
44 A New Approach to Target the Substrates of Persistent Atrial Fibrillation: The Sequential Substrate Ablation Approach Completed NCT02654353 Phase 4
45 Withdrawal Versus Continuation of Amiodarone in Successfully Treated Patients With Persistent Atrial Fibrillation Completed NCT00845780 Phase 4
46 Atrial Fibrillation and Congestive Heart Failure Trial Completed NCT00597077 Phase 4
47 Prevention of Atrial Fibrillation Following Noncardiac Thoracic Surgery Completed NCT00127712 Phase 4
48 Ablation of the Pulmonary Veins for Paroxysmal Afib Completed NCT00744874 Phase 4
49 Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation Completed NCT01447862 Phase 4
50 Prevention of Atrial Fibrillation Following Esophagectomy Completed NCT00420017 Phase 4

Search NIH Clinical Center for Atrial Fibrillation

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: atrial fibrillation

Genetic Tests for Atrial Fibrillation

Genetic tests related to Atrial Fibrillation:

id Genetic test Affiliating Genes
1 Atrial Fibrillation 29

Anatomical Context for Atrial Fibrillation

MalaCards organs/tissues related to Atrial Fibrillation:

39
Heart, Brain, Lung, Testes, Endothelial, Kidney, Neutrophil

Publications for Atrial Fibrillation

Articles related to Atrial Fibrillation:

(show top 50) (show all 2229)
id Title Authors Year
1
Patients' and physicians' perceptions and attitudes about oral anticoagulation and atrial fibrillation: a qualitative systematic review. ( 28086887 )
2017
2
Pacemaker-detected severe sleep apnea predicts new-onset atrial fibrillation. ( 28073884 )
2017
3
Effect of Interleukin-27 Genetic Variants on Atrial Fibrillation Susceptibility. ( 28055231 )
2017
4
The APPLE Score - A Novel Score for the Prediction of Rhythm Outcomes after Repeat Catheter Ablation of Atrial Fibrillation. ( 28085921 )
2017
5
Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. ( 28087176 )
2017
6
Gamma-glutamyl transferase and atrial fibrillation in patients with coronary artery disease. ( 27939920 )
2017
7
Elevated calprotectin in patients with atrial fibrillation with and without heart failure. ( 28276729 )
2017
8
End-points for catheter ablation of persistent atrial fibrillation. ( 28089875 )
2017
9
Excess of exercise increases the risk of atrial fibrillation. ( 28090681 )
2017
10
A frameshift deletion in the sarcomere gene MYL4 causes early-onset familial atrial fibrillation. ( 27742809 )
2017
11
Right Ventricular Structure and Function Are Associated With Incident Atrial Fibrillation: MESA-RV Study (Multi-Ethnic Study of Atherosclerosis-Right Ventricle). ( 28082528 )
2017
12
Atrial fibrillation in beta thalassemia major: how to perform effective screening and early detection. ( 28084158 )
2017
13
DNA sensors to assess the effect of VKORC1 and CYP2C9 gene polymorphisms on warfarin dose requirement in Chinese patients with atrial fibrillation. ( 28083852 )
2017
14
Screening for Atrial Fibrillation using Economical and accurate TechnologY (SAFETY)-a pilot study. ( 28087552 )
2017
15
Incidence of atrial fibrillation detected by continuous rhythm monitoring after acute myocardial infarction in patients with preserved left ventricular ejection fraction: results of the ARREST study. ( 28069838 )
2017
16
The role of adenosine challenge in catheter ablation for atrial fibrillation: A systematic review and meta-analysis. ( 28089454 )
2017
17
Rapid rest/stress regadenoson ungated perfusion CMR for detection of coronary artery disease in patients with atrial fibrillation. ( 28528431 )
2017
18
New-onset atrial fibrillation after percutaneous coronary intervention with stent: Updated proposal of an algorithm for the choice of oral anticoagulant and its dose. ( 28087220 )
2017
19
Decreased Mortality With Beta-Blockers inA Patients With Heart Failure and Coexisting Atrial Fibrillation: An AF-CHF Substudy. ( 28089316 )
2017
20
Fibrillatory wave amplitude on transesophageal ECG as a marker of left atrial low-voltage areas in patients with persistent atrial fibrillation. ( 28090710 )
2017
21
Analysis of Circulating miR-1, miR-23a, and miR-26a in Atrial Fibrillation Patients Undergoing Coronary Bypass Artery Grafting Surgery. ( 28422282 )
2017
22
Fall risk and anticoagulation for atrial fibrillation in the elderly: A delicate balance. ( 28084982 )
2017
23
Atrial fibrillation associated with Wolff-Parkinson-White syndrome in a patient with concomitant Brugada syndrome. ( 28491758 )
2017
24
Effect of Shensong Yangxin on the Progression of Paroxysmal Atrial Fibrillation is Correlated with Regulation of Autonomic Nerve Activity. ( 28091409 )
2017
25
Relationship between Angiotensin Converting Enzyme, Apelin, and New-Onset Atrial Fibrillation after Off-Pump Coronary Artery Bypass Grafting. ( 28299332 )
2017
26
Prognostic Impact of Atrial Fibrillation and New Risk Score of Its Onset in Patients at High Risk of Heart Failurea88- A Report From the CHART-2 Study. ( 28090009 )
2017
27
Clinical utility and functional analysis of variants in atrial fibrillation-associated locus 4q25. ( 28087289 )
2017
28
Is epicardial fat depot associated with atrial fibrillation? A systematic review and meta-analysis. ( 28087595 )
2017
29
Gain-of-function mutations in GATA6 lead to atrial fibrillation. ( 27756709 )
2017
30
Left Atrial Mechanical Function and Aortic Stiffness in Middle-aged Patients with the First Episode of Atrial Fibrillation. ( 28091404 )
2017
31
Is There an Interplay Between Adherence to Mediterranean Diet, Antioxidant Status, and Vascular Disease in Atrial Fibrillation Patients? ( 27577528 )
2016
32
Heartbeat: Is atrial fibrillation ablation effective in patients with hypertrophic cardiomyopathy? ( 27625352 )
2016
33
Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant. ( 27217043 )
2016
34
Prognostic Importance of Atrial Fibrillation Timing and Pattern in Adults with Congestive Heart Failure: a Systematic Review and Meta-Analysis. ( 27565044 )
2016
35
Impact of CYP2C19 gene polymorphism on warfarin maintenance doses in patients with non-valvular atrial fibrillation. ( 27356304 )
2016
36
Association between -44G/A and +71A/G polymorphisms in the connexin 40 gene and atrial fibrillation in Uyghur and Han populations in Xinjiang, China. ( 27813566 )
2016
37
Increased Serum Alkaline Phosphatase as a Predictor of Symptomatic Hemorrhagic Transformation in Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease. ( 27425768 )
2016
38
Influenza vaccination reduces hemorrhagic stroke risk in patients with atrial fibrillation: A population-based cohort study. ( 28089151 )
2016
39
Constitutive Expression of a Dominant Negative TGF-I^ Type II Receptor in the Posterior Left Atrium Leads to Beneficial Remodeling of Atrial Fibrillation Substrate. ( 27217399 )
2016
40
Severe Pulmonary Vein Stenosis Resulting From Ablation for Atrial Fibrillation: Presentation, Management, and Clinical Outcomes. ( 27793993 )
2016
41
The role of the atrial electromechanical delay in predicting atrial fibrillation in beta-thalassemia major patients. ( 27878421 )
2016
42
The Consult Guys - Risk With Atrial Fibrillation: A Guy Thing? ( 27653719 )
2016
43
Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. ( 26869393 )
2016
44
Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma. ( 27087288 )
2016
45
Olmesartan Reduces New-onset Atrial Fibrillation and Atrial Fibrillation Burden after Dual-chamber Pacemaker Implantation in Atrioventricular Block Patients. ( 27625082 )
2016
46
TCT-809 Stenting for the treatment of pulmonary vein stenosis after atrial fibrillation radiofrequency catheter ablation: initial experience with peripheral stents plus drug-coated balloons and coronary drug-eluting stents. ( 27970199 )
2016
47
Pitx2c increases in atrial myocytes from chronic atrial fibrillation patients enhancing IKs and decreasing ICa,L. ( 26714926 )
2016
48
Ranolazine improves oxidative stress and mitochondrial function in the atrium of acetylcholine-CaCl2 induced atrial fibrillation rats. ( 27208652 )
2016
49
Treatment of Chronic Atrial Fibrillation During Surgery for Rheumatic Mitral Valve Disease. ( 27849305 )
2016
50
Aspiration Thrombectomy of Acute Atrial Fibrillation-related Renal Artery Thromboembolism in a Patient with Horseshoe Kidney. ( 27354320 )
2016

Variations for Atrial Fibrillation

ClinVar genetic disease variations for Atrial Fibrillation:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 KCNQ1 NM_000218.2(KCNQ1): c.418A> G (p.Ser140Gly) single nucleotide variant Pathogenic rs120074192 GRCh37 Chromosome 11, 2549189: 2549189
2 SCN5A NM_000335.4(SCN5A): c.1410C> G (p.Asn470Lys) single nucleotide variant Pathogenic rs199473115 GRCh37 Chromosome 3, 38646328: 38646328
3 SCN5A NM_198056.2(SCN5A): c.1963G> A (p.Glu655Lys) single nucleotide variant Pathogenic/Likely pathogenic rs199473579 GRCh37 Chromosome 3, 38640469: 38640469
4 KCNQ1 NM_000218.2(KCNQ1): c.421G> A (p.Val141Met) single nucleotide variant Pathogenic rs199472687 GRCh37 Chromosome 11, 2549192: 2549192
5 KCNQ1 NM_000218.2(KCNQ1): c.625T> C (p.Ser209Pro) single nucleotide variant Pathogenic rs199472705 GRCh37 Chromosome 11, 2592575: 2592575

Expression for Atrial Fibrillation

Search GEO for disease gene expression data for Atrial Fibrillation.

Pathways for Atrial Fibrillation

Pathways related to Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.73 ADRB1 KCNE1 KCNJ2 KCNQ1 NPPB SCN1B
2
Show member pathways
12.7 SCN1B SCN2B SCN3B SCN4B SCN5A
3
Show member pathways
12.58 KCNE1 KCNE2 KCNJ2 KCNQ1 NPPA SCN1B
4
Show member pathways
12.51 SCN1B SCN2B SCN3B SCN4B SCN5A
5 12.21 KCNA5 KCNE1 KCNE2 KCNJ2 KCNQ1
6
Show member pathways
12.03 ADRB1 KCNE2 KCNJ2 KCNQ1
7 12.01 KCNQ1 SCN3B SCN4B SCN5A
8
Show member pathways
11.95 HCN4 KCNA5 KCNJ2 KCNQ1
9
Show member pathways
11.9 SCN1B SCN2B SCN3B SCN4B SCN5A
10 11.55 ACE ADRB1 AGT KCNJ2
11
Show member pathways
11.43 KCNE1 KCNE2 KCNQ1 SCN1B SCN2B SCN3B
12 11.18 ADRB1 GJA5 HCN4 KCNA5 KCNE1 KCNE2
13 11.13 SCN1B SCN2B SCN3B SCN4B SCN5A
14 10.9 HCN4 KCNE1 KCNJ2 KCNQ1

GO Terms for Atrial Fibrillation

Cellular components related to Atrial Fibrillation according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 Z disc GO:0030018 9.62 KCNA5 KCNE1 SCN3B SCN5A
2 voltage-gated potassium channel complex GO:0008076 9.55 KCNA5 KCNE1 KCNE2 KCNJ2 KCNQ1
3 T-tubule GO:0030315 9.54 KCNJ2 SCN1B SCN5A
4 intercalated disc GO:0014704 9.43 GJA5 KCNA5 KCNJ2 SCN1B SCN4B SCN5A
5 voltage-gated sodium channel complex GO:0001518 9.02 SCN1B SCN2B SCN3B SCN4B SCN5A
6 integral component of membrane GO:0016021 10.25 ACE ADRB1 GJA5 HCN4 KCNA5 KCNE1
7 plasma membrane GO:0005886 10.1 ACE ADRB1 F2 GJA5 HCN4 KCNA5

Biological processes related to Atrial Fibrillation according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
id Name GO ID Score Top Affiliating Genes
1 regulation of postsynaptic membrane potential GO:0060078 9.99 HCN4 SCN1B SCN2B SCN3B SCN4B SCN5A
2 cardiac muscle contraction GO:0060048 9.97 KCNQ1 SCN1B SCN2B SCN3B SCN4B SCN5A
3 regulation of blood pressure GO:0008217 9.95 ACE AGT NPPA NPPB
4 regulation of sodium ion transmembrane transporter activity GO:2000649 9.91 SCN1B SCN2B SCN3B SCN4B
5 cellular response to mechanical stimulus GO:0071260 9.89 AGT KCNJ2 NPPA
6 positive regulation of sodium ion transport GO:0010765 9.88 SCN1B SCN3B SCN4B SCN5A
7 ventricular cardiac muscle cell action potential GO:0086005 9.88 GJA5 KCNE1 KCNE2 KCNQ1 SCN3B SCN5A
8 cellular response to cAMP GO:0071320 9.87 HCN4 KCNE1 KCNQ1
9 potassium ion export GO:0071435 9.87 KCNA5 KCNE1 KCNE2 KCNQ1
10 SA node cell action potential GO:0086015 9.86 GJA5 HCN4 SCN3B SCN5A
11 cardiac conduction GO:0061337 9.86 GJA5 KCNE1 KCNE2 KCNJ2 KCNQ1 SCN1B
12 regulation of heart rate GO:0002027 9.85 AGT HCN4 SCN5A
13 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.85 KCNA5 KCNQ1 NPPA SCN5A
14 atrial cardiac muscle cell action potential GO:0086014 9.85 KCNA5 KCNQ1 NUP155 SCN3B SCN5A
15 membrane depolarization GO:0051899 9.84 SCN1B SCN3B SCN5A
16 regulation of vasoconstriction GO:0019229 9.84 ACE AGT KCNA5
17 positive regulation of heart rate GO:0010460 9.83 KCNQ1 NPPA SCN3B
18 regulation of blood vessel size GO:0050880 9.83 AGT NPPA NPPB
19 membrane repolarization during action potential GO:0086011 9.83 KCNE1 KCNE2 KCNJ2 KCNQ1
20 regulation of atrial cardiac muscle cell membrane depolarization GO:0060371 9.83 GJA5 SCN1B SCN2B SCN3B SCN5A
21 positive regulation of potassium ion transmembrane transport GO:1901381 9.82 KCNE1 KCNJ2 KCNQ1
22 regulation of vasodilation GO:0042312 9.82 ACE GJA5 NPPB
23 regulation of membrane repolarization GO:0060306 9.81 KCNE2 KCNJ2 KCNQ1
24 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.81 KCNE1 KCNJ2 KCNQ1
25 membrane repolarization GO:0086009 9.8 KCNE1 KCNE2 KCNQ1
26 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.8 KCNE1 KCNE2 KCNQ1
27 regulation of ventricular cardiac muscle cell membrane depolarization GO:0060373 9.79 GJA5 SCN3B SCN5A
28 cardiac muscle cell action potential involved in contraction GO:0086002 9.76 KCNE1 KCNE2 KCNJ2 SCN1B SCN2B SCN3B
29 regulation of potassium ion transmembrane transport GO:1901379 9.72 KCNE1 KCNE2
30 positive regulation of renal sodium excretion GO:0035815 9.72 AGT NPPB
31 angiotensin maturation GO:0002003 9.72 ACE AGT
32 regulation of cardiac muscle cell contraction GO:0086004 9.71 KCNJ2 SCN5A
33 receptor guanylyl cyclase signaling pathway GO:0007168 9.71 NPPA NPPB
34 regulation of blood vessel diameter GO:0097746 9.71 ACE NPPB
35 positive regulation of cardiac muscle contraction GO:0060452 9.71 KCNQ1 NPPA
36 cell growth involved in cardiac muscle cell development GO:0061049 9.7 AGT NPPA
37 negative regulation of delayed rectifier potassium channel activity GO:1902260 9.7 KCNE1 KCNE2
38 regulation of delayed rectifier potassium channel activity GO:1902259